Search results
With new Enhertu data, an ADC could overtake chemo in breast cancer
BioPharma Dive via Yahoo Finance· 5 days agoStudy participants had already received one hormone therapy and a type of drug called a CDK 4/6...
Patient’s Dark Fantasy About Aetna Lands Him in Jail
The Daily Beast via Yahoo News· 3 days agoMany Americans loathe their health insurance providers.A majority say they have severe concerns about financial hardship due to medical bills—even with...
AstraZeneca’s breast cancer trial shows ‘unprecedented’ results | Honolulu Star-Advertiser
Honolulu Star-Advertiser· 5 days agoAstraZeneca and Daiichi Sankyo’s Enhertu slows the progression of breast cancer by about five months...
Women denied ‘wonder drug’ that could double terminal breast cancer life expectancy
Daily Telegraph· 4 days agoWomen with HER2-low or ultra-low breast cancer who took Enhertu lived without their cancer growing...
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support...
Morningstar· 6 days agoTempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm ...
Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.
The Wall Street Journal· 5 days agoMore patients can fend off the disease for months or years with targeted or immune-boosting drugs,...
Some drugmakers to cap cost of asthma inhalers at $35 a month
NBC NEWS· 6 days agoStarting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price...
Lung cancer treatment produces progression-free survival results in Phase III trial
Medical Xpress· 2 days agoOsimertinib, produced by AstraZeneca under the brand name Tagrisso, significantly extends the time patients live without their cancer worsening, offering the first effective ...
Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
Zacks via Yahoo Finance· 16 hours agoEmpaveli recorded sales of $25.6 million in the reported quarter, up 25.5% from the year-ago...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 4 days agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth...